Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Large Scale Biology Corp.

Latest From Large Scale Biology Corp.

Protein Production Start-Ups

Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.

BioPharmaceutical Innovation

How Big Can Bio-Rad Get?

Bio-Rad's having a great year, thanks to its presence in the fast-growing life sciences business of protein analysis, and its surprise success with a test for bovine spongiform encephalopathy (BSE). Founder and CEO David Schwartz built the business based on a mix of eclectic product lines into an $800 million force in life sciences and clinical diagnostics. But as he nears 80, the company is grappling with succession issues, as well as a sense that it needs to better integrate its disparate businesses.

BioPharmaceutical Medical Device

Can Two Toolkits Make a Sustainable Business?

Things went downhill for population genetics company Gemini Genomics PLC after its IPO in July 2000, the most successful public offering of a UK company that year. Less than twelve months after raising $97 million on Nasdaq (where it hoped for greater visibility than from a London listing, given the paucity of UK genomics companies), the company has been bought by the German-American Sequenom Inc., in an all-paper deal worth about $224 million . Taking into account Gemini's net assets of $81.4 million, this values its technology at less than $150 million, a far cry from the company's $450 million market capitalization at its IPO.

BioPharmaceutical Strategy

The Proteomic Evolution of Celera, Incyte and Myriad

Impatient with the progress of genomics, investors are looking to a new set of proteomics technologies to provide the necessary boost in research productivity. Celera, Incyte, and Myriad, the heads of which we interview in this article, have each created widely different strategies for accessing the new opportunities. Aside from differences in technology approaches, the strategies of all three firms attempt to directly address the investment world's dissatisfaction with platform models-the original business model of both Incyte and Celera. Myriad has taken a low-risk leap into the world of proteomics, spinning off its proteomics tools into a new database company that will map the proteome, delivering Myriad the information it needs for its own product discovery and development programs and selling it at the same time on a non-exclusive basis to subscribers.Celera is radically modifying its information-only strategy, transforming itself into a drug discovery company that will be assisted financially with proceeds from its database business, which will itself be boosted by new proteomic data Celera will create, review before others, and then make available to subscribers. Incyte is continuing to focus on selling information as its base business, but is adding proteomic features to its basic systems through acquisition and internal development. At the same time, it is trading access to its LifeSeq database to new proteomic technology developers for a share either of their downstream product revenues and/or rights to sell the information those products generate.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Biosource Technology
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Large Scale Biology Corp.
  • Senior Management
  • Ronald Artale, SVP, CFO
    Guy della Cioppa, PhD, SVP, Bus. Dev.
    Kevin J Ryan, Pres.
    Gary Wolfe, PhD, SVP, CSO
  • Contact Info
  • Large Scale Biology Corp.
    Phone: (707) 446-5501
    3333 Vaca Valley Pkwy.
    Ste. 1000
    Vacaville, CA 95688